Versant Capital Management’s Corcept Therapeutics CORT Stock Holding History

Versant Capital Management’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15K	Buy	172 +145	+537%	+$8.76K	﹤0.01%	2076
2026 Q1	$1.09K	Sell	27 -7	-21%	-$262	﹤0.01%	2643
2025 Q4	$1.18K	Buy	34 +7	+26%	+$550	﹤0.01%	2514
2025 Q3	$2.24K	Hold	27	–	–	﹤0.01%	2390
2025 Q2	$1.98K	Hold	27	–	–	﹤0.01%	2383
2025 Q1	$3.08K	Hold	27	–	–	﹤0.01%	2190
2024 Q4	$1.36K	Hold	27	–	–	﹤0.01%	2130
2024 Q3	$1.25K	Hold	27	–	–	﹤0.01%	1694
2024 Q2	$877	Hold	27	–	–	﹤0.01%	1703
2024 Q1	$680	Sell	27 -22	-45%	-$520	﹤0.01%	1632
2023 Q4	$1.59K	Sell	49 -57	-54%	-$1.56K	﹤0.01%	1366
2023 Q3	$2.89K	Hold	106	–	–	﹤0.01%	1177
2023 Q2	$2.36K	Buy	106 +22	+26%	+$506	﹤0.01%	1312
2023 Q1	$1.82K	Hold	84	–	–	﹤0.01%	1296
2022 Q4	$1.71K	Sell	84 -13	-13%	-$326	﹤0.01%	1178
2022 Q3	$2K	Buy	97 +9	+10%	+$241	﹤0.01%	1058
2022 Q2	$2K	Hold	88	–	–	﹤0.01%	1076
2022 Q1	$2K	Buy	88 +70	+389%	+$1.49K	﹤0.01%	1113
2021 Q4	$0	Hold	18	–	–	﹤0.01%	1458
2021 Q3	$0	Hold	18	–	–	﹤0.01%	1468
2021 Q2	$0	Hold	18	–	–	﹤0.01%	1467
2021 Q1	$0	Hold	18	–	–	﹤0.01%	1532
2020 Q4	$0	Hold	18	–	–	﹤0.01%	1363
2020 Q3	$0	Hold	18	–	–	﹤0.01%	1325
2020 Q2	$0	Hold	18	–	–	﹤0.01%	1330
2020 Q1	$0	Buy	+18	New	+$223	﹤0.01%	1361

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Versant Capital Management's CORT Position: Q2 2026 in Review

Versant Capital Management increased its Corcept Therapeutics (CORT) stake by 537% in Q2 2026, buying an estimated $8.76K and bringing the position to 172 shares worth $15K. The position accounts for ﹤0.01% of the portfolio, ranked #2076.

Versant Capital Management first reported a position in CORT in Q1 2020 and has held it in 26 quarters since. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

Versant Capital Management held 172 shares of Corcept Therapeutics worth $15K as of Q2 2026.
Versant Capital Management bought 145 Corcept Therapeutics shares in Q2 2026, an estimated $8.76K.
Corcept Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2076 holding.
Versant Capital Management first reported a position in Corcept Therapeutics in Q1 2020 and has held it in 26 quarters since.
422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.